Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online October 3, 2022.
Article Versions
- previous version (January 14, 2022 - 05:26).
- You are viewing the most recent version of this article.
Copyright & Usage
© PDA, Inc. 2022
Author Information
- Melisa J. Masuda-Herrera1,*,
- Joel P. Bercu1,
- Thomas H. Broschard2,
- Anders Burild3,
- Catrin Hasselgren4,
- Patricia Parris5,
- Lucie C. Ford6,
- Jessica Graham4,
- Brad Stanard7,
- Michele Comerford8,
- Daniel Lettiere8,
- Steffen Erler9,
- Courtney M. Callis10,
- Eric Morinello4,
- Wolfgang Muster11,
- Elizabeth A. Martin12,
- Troy R. Griffin13,
- Lee Nagao14 and
- Maureen Cruz14
- 1Nonclinical Safety and Pathobiology (NSP), Gilead Sciences, Inc., Foster City, CA, USA;
- 2Merck Healthcare KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany;
- 3Safety Sciences, Imaging and Data Management, Novo Nordisk A/S, Novo Nordisk Park 2760 Måløv, Denmark;
- 4Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080;
- 5Pfizer Worldwide Research and Development, Sandwich, United Kingdom;
- 6Department of Veterinary Integrative Biosciences, Interdisciplinary Faculty of Toxicology Program, Texas A&M University, 4466 TAMU, College Station, TX, 77843-4466;
- 7Ultragenyx Pharmaceutical Inc., Novato, CA;
- 8Pfizer Global Research & Development, Groton, CT, 06340;
- 9Wella Company, Berliner Allee 65, 64295 Darmstadt, Germany;
- 10Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN;
- 11Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland;
- 12Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom;
- 13Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, 19380; and
- 14Faegre Drinker Biddle & Reath LLP, Washington, DC
- ↵*Corresponding Author: Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, CA; E-mail: Melisa.Masuda-Herrera{at}gilead.com
